Clinical trials: Antipsychotics
Schizophrenia
A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Healthy Controls
The primary objective of this study is to compare the effect of two different antipsychotic compounds which are used in the treatment of schizophrenia (paliperidone ER and risperidone) at their target sites in two specific areas…
- Trial name
- NCT00934635
- Testing
- Paliperidone ER, Oral risperidone, PET Scan
- Where
- Germany
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Janssen-Cilag G.m.b.H
Insulin Resistance, Dyslipidemia
Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Antipsychotic Drugs in Healthy Humans
We hypothesized that short-term treatment with AP drugs induces insulin resistance through a mechanistic route that is independent of weight gain and that atypical drugs exert stronger effects than typical compounds in this…
- Trial name
- NCT00625170
- Testing
- olanzapine, Haloperidol
- Where
- Netherlands
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Delirium, Epileptics
Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy
To examine the effects of haloperidol, chlorpromazine, valproic acid and placebo, in conjunction with standardized non-pharmacologic interventions, in the first line treatment of agitated delirium in hospitalized patients with…
- Conditions
- Delirium, Epileptics, Neuroleptics
- Trial name
- NCT05431595
- Testing
- Haloperidol, Chlorpromazine, Valproate
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Bipolar Depression
Treatment Resistant Bipolar Depression
To determine if adding Escitalopram to current mood stabilizer (MS) or atypical antipsychotic (AA) will improve in rates similar to or better than adding a placebo (inactive pill)in resistant bipolar patients.
- Trial name
- NCT00272025
- Testing
- Escitalopram
- Where
- Canada
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Queen's University
Schizophrenia
A Study of the Effect of Food and Posture on the Pharmacokinetics of a Single Dose of ER OROS Paliperidone
The purposes of this study are to evaluate the effect of food on the pharmacokinetics of extended-release (ER) OROS paliperidone in healthy men, and to evaluate the effect of posture on the pharmacokinetics of ER OROS…
- Trial name
- NCT00838669
- Testing
- Extended release OROS paliperidone
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
HIV Infections
Interaction Between Fosamprenavir/Ritonavir and a Single-dose Olanzapine (FORZA)
The effect of fosamprenavir/ritonavir (steady state) on the pharmacokinetics of a single dose of olanzapine will be studied. In this study, the investigators expect an inducible effect of fosamprenavir/ritonavir on the CYP1A2 and…
- Trial name
- FORZA (NCT00977301)
- Testing
- fosamprenavir/ritonavir, olanzapine
- Where
- Netherlands
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Healthy, Pharmacokinetics of Quetiapine
Study to Evaluate the Effect of Multiple-dose of Fluvoxamine on the Plasma Concentration of Quetiapine (FK949E) in Healthy Male Volunteers
The objective of the study was to assess the effect of multiple-dose fluvoxamine on the pharmacokinetics of quetiapine (FK949E) in healthy adult male subjects. The safety of FK949E in the population was also evaluated.
- Trial name
- NCT01908296
- Testing
- FK949E, fluvoxamine
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Child Mental Disorders, Obesity
Healthy Bodies, Healthy Kids
The US prevalence of childhood-onset obesity and type 2 diabetes, both predictors of cardiovascular risk, have increased to epidemic proportions in recent decades.
- Conditions
- Child Mental Disorders, Obesity, Metabolic Syndrome
- Trial name
- NCT01222494
- Testing
- Behavioral Weight Loss, Diet and Exercise Education
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Parkinson's Disease Psychosis
Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis
Patients with Parkinson's disease (PD) sometimes experience symptoms affecting their movement, such as slowness, tremor, stiffness, and balance or walking problems.
- Trial name
- C-SAPP (NCT04373317)
- Testing
- Pimavanserin, Quetiapine
- Where
- 24 sites in United States
- Volunteers
- 358 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Schizophrenia
Predicting Antipsychotic Discontinuation in Psychosis
The purpose of this study is to determine whether dopamine synthesis capacity by using [18 fluorine(F)]-DOPA PET for patients with schizophrenia in the maintenance phase can predict treatment discontinuation.
- Trial name
- PADP (NCT02884518)
- Testing
- PET, clinical scale
- Where
- South Korea
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Schizophrenia
Pan European Collaboration on Antipsychotic Naive Schizophrenia (PECANS)
The investigators want to relate disturbances in first-episode schizophrenic patients in (dopaminergic) D2 receptors, brain structure, brain function, and information processing to each other and to psychopathology.
- Trial name
- PECANS (NCT01154829)
- Testing
- amisulpride, aripiprazole
- Where
- Denmark
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Schizophrenia, Schizoaffective Disorder
Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus
This preliminary study aims to investigate the mechanism of higher rates of type 2 diabetes mellitus in patients with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Delusional Disorder
- Trial name
- NCT00222807
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Schizophrenia
Standard Comprehensive Intervention to Treat First-episode Schizophrenia
Schizophrenia is not a curable but a treatable disease by antipsychotics. Kinds of atypical antipsychotics are widely used since 1990s' in China.
- Trial name
- NCT01057849
- Testing
- risperidone, olanzapine, Aripiprazole
- Where
- 6 sites in China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Peking University
Hyperlipidemia, Diabetes
Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness
The study was a 12-month, multi-centered, quasi-experimental design to assess point-of-care (POCT) screening/monitoring of subjects on antipsychotic agents for metabolic syndrome.
- Conditions
- Hyperlipidemia, Diabetes, Hypertension
- Trial name
- NCT02029989
- Testing
- Glucose and lipids, Glycosylated Hemoglobin A1c, Blood Pressure and Heart Rate
- Where
- United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Mental Disorders
Measurement of Cardiometabolic Risk in Antipsychotic-Treated Children
The proposed study aims to begin the multi-step process of establishing the reliability and validity of hepatic triglyceride content (HTGC) and carotid artery intima-media thickness (IMT) as biomarkers of cardiometablic risk in…
- Trial name
- NCT00894738
- Testing
- Testing (MRS, US, DEXA, blood tests)
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Lurasidone Cardiotoxicity, Schizophrenia Patients
Effects of Lurasidone on Left Ventricle Systolic Functions
The goal of our study to learn if lurasidone molecule which is used on patients with schizophrenia or bipolar disorder has any cardiotoxic effect.
- Conditions
- Lurasidone Cardiotoxicity, Schizophrenia Patients, Bipolar Disorders
- Trial name
- Lurasidone (NCT06695676)
- Testing
- Global Longitudinal Strain
- Where
- Turkey (Türkiye)
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Aydin Adnan Menderes University
Schizophrenia
Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study
Despite recent advances in the understanding and treatment of schizophrenia, this devastating disease still affects one percent of world's population.
- Trial name
- CBD-IS (NCT02051387)
- Testing
- Cannabidiol CR, Cannabidiol, Amisulpride
- Where
- 2 sites in Germany
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Central Institute of Mental Health, Mannheim
Schizophrenia
The Phase I Study of HS-10509 in Chinese Adult Subjects
The study is to evaluate the safety, tolerability, and PK characteristics following single administration of HS-10509 in healthy adults, and multiple administrations of HS-10509 in patients with schizophrenia.
- Trial name
- NCT06301074
- Testing
- HS-10509
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Schizophrenia
Comparing the Effects of Sertindole and Olanzapine on Cognition (SEROLA)
Cognition is one of the core symptoms of schizophrenia. This study is a head-to-head trial between olanzapine and sertindole with cognition as primary outcome.
- Trial name
- SEROLA (NCT00885690)
- Testing
- Sertindole, Olanzapine
- Where
- 2 sites in Denmark, Sweden
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Schizophrenia
Neurobiological and Neurocognitive Disturbances in First-episode Schizophrenia
We want to relate disturbances in first-episode schizophrenic patients in serotonin 5-HT2A receptors, brain structure, brain function, and information processing to each other and to psychopathology.
- Trial name
- NCT00207064
- Testing
- quetiapine
- Where
- 3 sites in Denmark
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Birte Glenthoj